1Pfaller MA , Diekema DJ. Epidemiology of invasive mycoses in North America [J]. Crit Rev Microbiol, 2010, 36( 1 ): 1-53.
2Haider S, Rotstein C, Horn D, et al. The Prospective Antifungal Therapy Alliance registry: A two-centre Canadian experience [J]. Can J Infect Dis Med Microbiol, 2014, 25( 1 ): 17-23.
6Ramage G, Mowat E, Jones B, et al. Our current understanding of fungal biofilms [J]. Crit Rev Microbiol, 2009, 35(4): 340-355.
7Kucharikova S, Tournu H, Laqrou K, et al. Detailed comparison of Candida alhicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin [J]. J Med Microbiol, 2011,60(9): 1261-1269.
8Cannon RD, Lamping E, Holmes AR, et al. Efflux-mediated antifungal drug resistance [J]. Clin Microbiol Rev, 2009, 22 (2): 291-321.
9Fauvart M, De Groote VN, Miehiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti- persister therapies [J]. J Med Micmbiol, 201 l, 60(6): 600-709.
10Cannon RD, Lamping E, Holmes AR, et al. Candida albicans drug resistance another way to cope with stress [J]. Microbiology, 2007, 153( 10): 3211-3217.
3Wayne PA. Method for antifungal disk diffusion susceptibility testing in yeasts[S]. Approved guideline,CLSl M44-A, Clinical Laboratory Standards Institute,2002.
4Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infec- tions[J]. Lancet Infect Dis,2011,11(2) :142-151.
5Pfaller MA. Diekema DJ. Epidemiology of invasive candidiasis:a persistent public health problem[ J]. ClinMicrobiol Rev, 2007 , 20( 1 ) :133-163.
6Cabral ME, Figueroa LI, Farina JI. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae and Candida utilis-bioassays and ergosterol quantifica- tion [ J ]. Rev Iberoam Micol, 2013,30 ( 1 ) :31-38.
7Menezes EA,VasconeelosJOnior AA,Silva CL,et al. In vitro syn- ergism of simvastatin and fluconazole against Candida species [ J ]. Rev Inst Med Trop Sao Paulo,2012 ,54 (4) : 197-199.
8Bink A, Kucharikovd S, Neirinek B, et al. The nonsteroidal an- tiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms [ J ]. Infect Dis, 2012,206( 11 ) :1790-1797.
9Argenta JS, Alves SH, Silveira F, et al. In vitro and in vivo sus- ceptibility of two-drug and three-drug combinations of terbin- afine, itraconazole, caspofungin, ibuprofen and fluvastatin a- gainst Pythiuminsidiosum [ J ]. Vet Microbiol, 2012,157 ( 1-2 ) : 137-142.
10Kofla G, Turner V, Schulz B, et al. Doxorubicin induces drug ef- flux pumps in Candida albicans [J]. Med Mycol,2011,49(2) : 132-142.
